Summary
The potential for pharmacokinetic interactions between moxonidine and digoxin at steady-state was investigated in 15 healthy male volunteers. Multiple oral doses of 0.2mg moxonidine twice daily and 0.2mg digoxin once daily were administered alone and in combination in a randomised 3-period crossover design. The drugs were administered for at least 5 days.
The results indicate that neither moxonidine nor digoxin influences the pharmacokinetics of the other drug under steady-state conditions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armah BI. Unique presynaptic α 2-receptor selectivity and specificity of the antihypertensive agent moxonidine. Arzneimittel-Forschung 38: 1435–1442, 1988
CPMP Working Party on Efficacy of Medicinal Products. Note for guidance: investigation of bioavailability and bioquivalence (III/54/89-EN), 1991
Ernsberger P. Moxonidine, a second-generation centrally-acting antihypertensive, binds selectively to imidazole sites in the ventrolateral medulla (VLM) and kidney. Pharmacologist 32: 191, 1990
Gardner MJ, Altman DG. Confidence intervals rather than p-values: estimation rather than hypothesis testing. British Medical Journal 292: 746–750, 1986
Kirch W, Hutt HJ, Plänitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clinical Pharmacokinetics 15: 245–253, 1988
Reuning RH, Geraets DR. Digoxin. In Evans et al. (Eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, pp. 570–623, American Therapeutics Inc., Spokane, 2nd ed. 1986
Schuirman DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Bio-pharmaceutics 15: 657–680, 1987
Schwarz W, Kandziora J. Langzeiterfahrungen mit Moxonidin, einem neuen Antihypertensivum. Fortschritte der Medizin 108: 616–620, 1990
Steinijans VW, Hartmann M, Huber R, Radtke HW. Lack of pharmacokinetic interaction as an equivalence problem. International Journal of Clinical Pharmacology, Therapy and Toxicology 29: 323–328, 1991
Theodor R, Weimann HJ, Weber W, Michaelis K. Absolute bioavailability of moxonidine. European Journal of Drug Metabolism and Pharmacokinetics 16: 153–159, 1991
Trenk D, Wagner F, Jähnchen E, Plänitz V. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers. Journal of Clinical Pharmacology 27: 988–993, 1987
Victor N. On clinically relevant differences and shifted null hypotheses. Methods of Information in Medicine 26: 109–116, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pabst, G., Weimann, HJ. & Weber, W. Lack of Pharmacokinetic Interactions Between Moxonidine and Digoxin. Clin. Pharmacokinet. 23, 477–481 (1992). https://doi.org/10.2165/00003088-199223060-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199223060-00007